Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
2023
DOI: 10.3389/fddsv.2023.1222655
|View full text |Cite
|
Sign up to set email alerts
|

Yin-yang in drug discovery: rethinking de novo design and development of predictive models

Abstract: Chemical and biological data are the cornerstone of modern drug discovery programs. Finding qualitative yet better quantitative relationships between chemical structures and biological activity has been long pursued in medicinal chemistry and drug discovery. With the rapid increase and deployment of the predictive machine and deep learning methods, as well as the renewed interest in the de novo design of compound libraries to enlarge the medicinally relevant chemical space, the balance between quantity and qua… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3
1

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 133 publications
0
3
0
Order By: Relevance
“…Target–ligand interaction is identified by analyzing the interaction energies, electrostatic forces and van der Waals forces using algorithms or experimental data ( Du et al, 2016 ). The third step is hit discovery, which is mainly performed using two methods: de novo design and virtual screening ( Chávez-Hernández et al, 2023 ; Stanley and Segler, 2023 ). In the virtual screening approach, millions of drug-like compounds are docked to a target using computer algorithms and ranked according to their binding affinity ( Lionta et al, 2014 ).…”
Section: Structure-based Drug Designmentioning
confidence: 99%
“…Target–ligand interaction is identified by analyzing the interaction energies, electrostatic forces and van der Waals forces using algorithms or experimental data ( Du et al, 2016 ). The third step is hit discovery, which is mainly performed using two methods: de novo design and virtual screening ( Chávez-Hernández et al, 2023 ; Stanley and Segler, 2023 ). In the virtual screening approach, millions of drug-like compounds are docked to a target using computer algorithms and ranked according to their binding affinity ( Lionta et al, 2014 ).…”
Section: Structure-based Drug Designmentioning
confidence: 99%
“…4 In the same context, different types of molecular representations have enabled improved searches and expanded applications in various areas of chemistry. Examples include the development of new chemical compounds (de novo design), 5,6 property predictions such as absorption, distribution, metabolism, and excretion (ADME), 7 relationships (SARs), structure−properties relationships (SPRs), 8 and development of new chemical descriptors. 9 Notable examples of molecular descriptors commonly employed in drug discovery applications include structural fingerprints and molecular properties.…”
Section: ■ Introductionmentioning
confidence: 99%
“…In the same context, different types of molecular representations have enabled improved searches and expanded applications in various areas of chemistry. Examples include the development of new chemical compounds (de novo design), 4,5 properties prediction such as absorption, distribution, metabolism, and excretion (ADME), 6 structure-activity relationships (SAR), and structure-properties relationships (SPR), 7 and development of new chemical descriptors. 8 Notable examples of molecular descriptors commonly employed in drug discovery applications include structural fingerprints and molecular properties.…”
Section: Introductionmentioning
confidence: 99%